Modality
Peptide
MOA
PD-L1i
Target
Menin
Pathway
Tau
Endometrial CaMDSAML
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
Jul 2022
→ Jan 2027
Phase 3Current
NCT06682714
20 pts·AML
2022-07→2027-01·Recruiting
20 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-242mo awayNDA· MDS
2027-01-1710mo awayPh3 Readout· AML
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P3
Recruit…
Catalysts
NDA
2026-05-24 · 2mo away
MDS
Ph3 Readout
2027-01-17 · 10mo away
AML
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06682714 | Phase 3 | AML | Recruiting | 20 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |